Human microbiomes in cancer development and therapy
Chenglai Xia,
Jiyan Su,
Can Liu,
Zhikai Mai,
Shuanghong Yin,
Chuansheng Yang,
Liwu Fu
Affiliations
Chenglai Xia
Affiliated Foshan Maternity and Chlid Healthcare Hospital Southern Medical University, Foshan, China; School of Pharmaceutical Sciences, Southern Medical University Guangzhou China
Jiyan Su
Affiliated Foshan Maternity and Chlid Healthcare Hospital Southern Medical University, Foshan, China; School of Pharmaceutical Sciences, Southern Medical University Guangzhou China
Can Liu
Affiliated Foshan Maternity and Chlid Healthcare Hospital Southern Medical University, Foshan, China; School of Pharmaceutical Sciences, Southern Medical University Guangzhou China
Zhikai Mai
Affiliated Foshan Maternity and Chlid Healthcare Hospital Southern Medical University, Foshan, China; School of Pharmaceutical Sciences, Southern Medical University Guangzhou China
Shuanghong Yin
Affiliated Foshan Maternity and Chlid Healthcare Hospital Southern Medical University, Foshan, China; School of Pharmaceutical Sciences, Southern Medical University Guangzhou China
Chuansheng Yang
Department of Head‐Neck and Breast Surgery Yuebei People's Hospital of Shantou University Shaoguan China
Liwu Fu
State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine; Guangdong Esophageal Cancer Institute; Sun Yat‐sen University Cancer Center Guangzhou People's Republic of China
Abstract Colonies formed by bacteria, archaea, fungi, and viral groups and their genomes, metabolites, and expressed proteins constitute complex human microbiomes. An increasing evidences showed that carcinogenesis and disease progression were link to microbiomes. Different organ sources, their microbial species, and their metabolites are different; the mechanisms of carcinogenic or procancerous are also different. Here, we summarize how microbiomes contribute to carcinogenesis and disease progression in cancers of the skin, mouth, esophagus, lung, gastrointestinal, genital, blood, and lymph malignancy. We also insight into the molecular mechanisms of triggering, promoting, or inhibiting carcinogenesis and disease progress induced by microbiomes or/and their secretions of bioactive metabolites. And then, the strategies of application of microorganisms in cancer treatment were discussed in detail. However, the mechanisms by which human microbiomes function are still poorly understood. The bidirectional interactions between microbiotas and endocrine systems need to be clarified. Probiotics and prebiotics are believed to benefit human health via a variety of mechanisms, in particular, in tumor inhibition. It is largely unknown how microbial agents cause cancer or how cancer progresses. We expect this review may open new perspectives on possible therapeutic approaches of patients with cancer.